

12/21/01  
J1044 U.S. PTO

12-31-01

Benson A

PTO/SB/05 (2/98)

Approved for use through 09/30/2000. OMB 0651-0032

Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) inside this box → ☐

# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 C.F.R. §1.53(b))

Attorney Docket No.

PC11028AJAK

First Named Inventor or Application Identifier

L. Kathryn Durham

Title

Methods, Compositions and Kits Relating to Cardiovascular Disease

Express Mail Label No.

EL911725610US

## APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. ☒ \*Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit an original, and a duplicate for fee processing)
  2. ☒ Specification [Total Pages (preferred arrangement set forth below)
    - Descriptive title of the Invention
    - Cross References to Related Applications
    - Statement Regarding Fed sponsored R&D
    - Reference in Microfiche Appendix
    - Background of the Invention
    - Brief Summary of the Invention
    - Brief Description of the Drawings (if filed)
    - Detailed Description
    - Claim(s)
    - Abstract of the Disclosure
  3. ☒ Drawing(s) (35 U.S.C. 11.3) [Total sheets   - 4. ☒ Oath or Declaration [Total pages   - a. ☒ Newly executed (original or copy)
  - b. ☐ Copy from a prior application (37 CFR §1.63(d))  
(for continuation/divisional with Box 17 completed)  
[Note Box 5 below]
  - i. ☐ DELETION OF INVENTOR(S)  
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§1.63(d)(2) and 1.33(b).
5. ☐ Incorporation By Reference (useable if Box 4b is checked)  
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

## ADDRESS TO:

Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

6. ☐ Microfiche Computer Program (Appendix)
7. Nucleotide and/or Amino Acid Sequence Submission  
(if applicable, all necessary)
  - a. ☒ Computer Readable Copy
  - b. ☒ Paper Copy (identical to computer copy)
  - c. ☒ Statement verifying identity of above copies

## ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 C.F.R. §3.73(b) Statement ☐ Power of Attorney  
(when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
14. ☐ \*Small Entity ☐ Statement filed in prior application,  
Statement(s) Status still proper and desired  
(PTO/SB/09-12)
15. ☐ Certified Copy of Priority Document(s)  
(if foreign priority is claimed)
14. ☐ Other: Priority Claim

\*NOTE FOR ITEMS 1 & 14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:


☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: \_\_\_\_\_ / \_\_\_\_\_

Prior application information: Examiner \_\_\_\_\_ Group/Art Unit: \_\_\_\_\_

## 18. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Label (Insert Customer No. or Attach bar code label here) or ☒ Correspondence address below

Name	Gregg C. Benson					
Address	Pfizer Inc.					
Address	Patent Department, MS 4159, Eastern Point Road					
City	Groton	State	CT	Zip Code	06340	
Country	United States Of America	Telephone	1-(860)-441-4901	Fax	1-(860)-441-5221	

NAME (Print/type)	Jennifer A. Kispart	Registration No. (Attorney/Agent)	40,049
Signature		Date	12/21/01

UTILITY TRANSMITTAL PTO SB 05, 9/99, (1/1)

## FEE TRANSMITTAL

Patent fees are subject to annual revision on October 1.  
These are the fees effective October 1, 2001.

Small Entity payments must be supported by a small entity statement,  
otherwise large entity fees must be paid See Forms PTO/SB/09-12.

See 37 C.F.R. §§ 1.27 and 1.28.

**Total Amount of Payment** (\$1,382.00)

### Complete if Known

Application Number	To be assigned
Filing Date	Herewith
First Named Inventor	L. Kathryn Durham
Examiner Name	To be assigned
Group/Art Unit	To be assigned
Attorney Docket No.	PC11028AJAK

### METHOD OF PAYMENT (check one)

1. ☒ The commissioner is hereby authorized to charge indicated fees and credit any over payments to:

Deposit Account Number: 16-1445

Deposit Account Name: Pfizer Inc

☒ Charge Any Additional 37 Fee Required Under C.F.R. §§ 1.1.6 and 1.17 ☐ Charge the Issue Fee Set in 37 C.F.R. § 1.1.8 at the Mailing of the Notice of Allowance.

2. ☐ Payment Enclosed:

☐ Check ☐ Money Order ☐ Other

### FEE CALCULATION

#### 1. BASIC FILING FEE

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description	Fee Paid
101	740	201	370	Utility filing fee	740.00
106	330	206	165	Design filing fee	
107	510	207	255	Plant filing fee	
108	740	208	370	Reissue filing fee	
114	160	214	80	Provisional filing fee	
<b>SUBTOTAL (1)</b> (\$)					740.00

#### 2. EXTRA CLAIM FEES

Total Claims	Extra Claims	Fee from below	Fee Paid
37	-20**= 17	X 18.00	= 306.00
Independent Claims: 7	- 3**= 4	X 84.00	= 336.00
Multiple Dependent			

\*\* or number previously paid, if greater; For Reissues, see below

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
103	18	203	9	Claims in excess of 20
102	84	202	42	Independent claims in excess of 3
104	280	204	140	Multiple dependent claim, if not paid
109	84	209	42	**Reissue independent claims over original patent
110	18	210	9	**Reissue claims in excess of 20 and over original patent
SUBTOTAL (2)				(\$) 642.00


### FEE CALCULATION (continued)

#### 3. ADDITIONAL FEES

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description	Fee Paid
105	130	205	65	Surcharge - late fee or oath	
127	50	227	25	Surcharge-late provisional filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	400	216	200	Extension for reply within second month	
117	920	217	460	Extension for reply within third month	
118	1,440	218	720	Extension for reply within fourth month	
128	1,960	228	980	Extension for reply within fifth month	
119	320	219	160	Notice of Appeal	
120	320	220	160	Filing a brief in support of an appeal	
121	280	221	140	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,280	241	640	Petition to revive - unintentional	
142	1,280	242	640	Utility issue fee (or reissue)	
143	460	243	230	Design issue fee	
144	620	244	310	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Petitions related to provisional applications	
126	180	126	180	Submission of Information Disclosure Statement	
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	740	246	370	Filing a submission after final rejection (37 CFR 1.129(a))	
149	740	249	370	For each additional invention to be examined (37 CFR 1.129(b))	
Other Fee (specify)					
Other Fee (specify)					
<b>SUBTOTAL (3)</b> (\$)					0

\*Reduced by Basic Filing Fee Paid

### SUBMITTED BY


Type or Printed Name	Jennifer A. Kispert	Complete (if Applicable)	
Signature		Reg. Number	40,049
Date	12/21/01	Deposit Account	16-1445
		User ID	

EXPRESS MAIL NO. EL911729610US

FEE TRANSMITTAL PTO SB 17.DOT 10/01

I hereby certify that this correspondence is being deposited with the United States Postal Service as express mail in an envelope addressed to:  
Director - U.S. Patent and Trademark Office, Washington, D.C. 20231 on this 21st day of December, 2001.

By

  
(Signature of person mailing)  
Janice M. Denison  
(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: **L. KATHRYN DURHAM, ET AL.** :

APPLICATION NO.: **TO BE ASSIGNED**

: Examiner: **To Be Assigned**

FILING DATE: **HEREWITH**

: Group Art Unit: **To Be Assigned**

TITLE: **METHODS, COMPOSITIONS AND KITS** :  
**RELATING TO CARDIOVASCULAR DISEASE**

Director - U.S. Patent and Trademark Office  
Washington, D.C. 20231


STATEMENT REGARDING SUBMISSION  
OF SEQUENCE LISTING UNDER 37 C.F.R. §1.821(f)

I hereby state that the information recorded in computer readable form is identical to  
the written sequence listing.

Respectfully submitted,

Date:

12/21/01



Jennifer A. Kispert  
Attorney for Applicant(s)  
Reg. No. 40,049

Pfizer Inc.  
Patent Department, MS 4159  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 715-5747

EXPRESS MAIL NO. EL911725610US

100322041-1 12/21/01